NAFLD (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis)
NAFLD is a common liver disease with extensive fat build up in liver. Some patients continue to progress to more severe liver damage, manifested by lobular inflammation, hepatocyte damage and fibrosis, as knowns as NASH. Abnormal liver fat accumulation by itself associates with more risks of cardiovascular diseases. In addition, NASH can progress to more serious, life-threatening clinical outcomes, including cirrhosis, hepatocellular carcinoma, liver transplantation, and even death.

The growing prevalence of NAFLD and NASH parallels with the dramatic rise in population of obesity and metabolic syndrome in global and China. One study estimated 25% people worldwide have NAFLD, and by 2030 there will be 27M and 48M NASH patients in China and U.S., respectively.
Treatment for NASH is limited to life style modification. No pharmacological treatment has been approved in major market yet.
Immune-related diseases
The immune system is the foundation of our heathy lives, for defense against foreign invaders and maintenance of homeostasis within our body.

Many diseases stem from an imbalance in immune system:
  • • Infection: invasion by harmful bacteria, viruses and other pathogens
  • • Allergy: overactivation to environmental antigens
  • • Autoimmune diseases: overactivation to self-antigens
  • • Cancer: failure of clearance of cancer cells

There are more than 100 different autoimmune diseases and even more different cancers that affect people around the world, and many of them have no effective treatment yet.
Eccogene immune programs emerges from de novo target discovery in immunometabolism platform and active collaboration with external partners for novel targets